Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2018

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:Certolizumab PegolFDAFDA approvalplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)

FDA Clears Pfizer’s Xeljanz for Inflammatory Bowel Disease

Reuters Staff  |  May 31, 2018

(Reuters)—The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc’s drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis. The effectiveness of Xeljanz (tofacitinib) in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent…

Filed under:Drug Updates Tagged with:Pfizer Inc.TofacitinibU.S. Food and Drug Administrationulcerative colitisXeljanz

Novartis Receives EU Approval for Infliximab Biosimilar Zessly

Reuters Staff  |  May 30, 2018

ZURICH (Reuters)—Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult and pediatric Crohn’s disease, adult and pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis,…

Filed under:Drug Updates Tagged with:EU approvalinfliximab biosimilarNovartisZessly

One Step Closer to Personalized Medicine for RA Patients

Carina Stanton  |  May 30, 2018

New research is translating the molecular signals in RA patients to better understand the earliest signs of disease. The work on using these signs to test the effects of RA treatment may help rheumatologists determine the most effective treatment for individuals…

Filed under:ConditionsRheumatoid Arthritis

Affiliate Society Council Meeting Provides Motivation, Fellowship, Opportunity

Kelly Tyrrell  |  May 21, 2018

On Wednesday, May 16, 2018, the ACR’s Affiliate Society Council (ASC) convened a meeting in Washington, D.C., in conjunction with the ACR’s Advocacy Leadership Conference. Despite inclement weather that delayed or cancelled numerous flights, several rheumatology representatives from states across the U.S. attended the meeting in person, while others participated by conference call. “It was…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affiliate Society Council (ASC)biosimilar legislationcopay accumulatorsnon-medical switchingstep therapyWashington D.C.

6 Things Endocrinologists Want Rheumatologists to Know

Vanessa Caceres  |  May 17, 2018

In your daily contact with rheumatology patients, you likely come across several who have type 1 or 2 diabetes. Are you doing all you can to maximize their treatment? Most physicians know about the damaging health effects of uncontrolled diabetes. From vision loss to kidney failure to nerve damage, those with diabetes require regular vigilance…

Filed under:Conditions Tagged with:collaborationcommunicationdiabetesinterdisciplinarySteroids

Researchers Test Belimumab in Scleroderma

Catherine Kolonko  |  May 17, 2018

A yearlong pilot study that evaluated the safety and efficacy of belimumab in a small group of patients with early diffuse systemic sclerosis found no significant difference in the number of adverse events between those treated with the drug and those who received a placebo. Currently, no drugs are approved specifically for the treatment of…

Filed under:Drug UpdatesSystemic Sclerosis Tagged with:belimumabSScSystemic sclerosis

Protecting Patient Care on All Fronts: A Conversation with Kent “Kwas” Huston, MD, ACR Government Affairs Committee Member

Carina Stanton  |  May 4, 2018

Kent “Kwas” Huston, MD, remembers the conversations he had with his father’s rheumatology patients in Kansas City, Mo., when he visited his father’s practice while he was growing up. “They shared what a difference he made for them,” Dr. Huston explains. Dr. Huston also saw firsthand the importance of rheumatology care. His mother was diagnosed…

Filed under:Profiles Tagged with:Government Affairs Committee (GAC)Kent “Kwas” Huston

International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2018

In Japan the use of guselkumab to treat erythrodermic, plaque and pustular psoriasis is approved, and anakinra is now indicated for Still’s disease in the E.U…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:adalimumabadult Still's Diseaseanakinraerythrodermic psoriasisguselkumabJapanplaque psoriasisPsoriasispustular psoriasis

Telehealth Is Helping the Underserved

Linda Childers  |  April 26, 2018

For many uninsured and underinsured patients in Yuba City, Calif., seeing a rheumatologist used to mean taking a day off from work and driving 108 miles, roundtrip, to the University of California Davis Medical Center. That changed this year when patients were offered the option of having a telemedicine consultation with a rheumatologist as part…

Filed under:Information TechnologyTechnology Tagged with:MAVENMedical Alumni Volunteer Expert Networktelehealthtelemedicine

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences